Evidence map›Paper›PMID 36768426›Full record

ReviewInternational journal of molecular sciences2023

Metallic Nanosystems in the Development of Antimicrobial Strategies with High Antimicrobial Activity and High Biocompatibility.

Karol Skłodowski, Sylwia Joanna Chmielewska-Deptuła, Ewelina Piktel, Przemysław Wolak, Tomasz Wollny, Robert Bucki

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. ACS omega · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. International journal of nanomedicine · 2026
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karol SkłodowskiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, 15-222 Bialystok, Poland.
Sylwia Joanna Chmielewska-DeptułaDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, 15-222 Bialystok, Poland.
Ewelina PiktelIndependent Laboratory of Nanomedicine, Medical University of Bialystok, 15-222 Bialystok, Poland.
Przemysław WolakInstitute of Medical Science, Collegium Medicum, Jan Kochanowski University of Kielce, IX Wieków Kielce 19A, 25-317 Kielce, Poland.ORCID 0000-0003-4450-5011
Tomasz WollnyHoly Cross Oncology Center of Kielce, Artwińskiego 3, 25-734 Kielce, Poland.
Robert BuckiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, 15-222 Bialystok, Poland.ORCID 0000-0001-7664-9226

Funding

Medical University of Bialystok, Poland SUB/1/DN/22/005/1122National Science Centre, Poland UMO-2018/31/B/NZ6/02476
6 · The paper itself

Abstract

Antimicrobial resistance is a major and growing global problem and new approaches to combat infections caused by antibiotic resistant bacterial strains are needed. In recent years, increasing attention has been paid to nanomedicine, which has great potential in the development of controlled systems for delivering drugs to specific sites and targeting specific cells, such as pathogenic microbes. There is continued interest in metallic nanoparticles and nanosystems based on metallic nanoparticles containing antimicrobial agents attached to their surface (core shell nanosystems), which offer unique properties, such as the ability to overcome microbial resistance, enhancing antimicrobial activity against both planktonic and biofilm embedded microorganisms, reducing cell toxicity and the possibility of reducing the dosage of antimicrobials. The current review presents the synergistic interactions within metallic nanoparticles by functionalizing their surface with appropriate agents, defining the core structure of metallic nanoparticles and their use in combination therapy to fight infections. Various approaches to modulate the biocompatibility of metallic nanoparticles to control their toxicity in future medical applications are also discussed, as well as their ability to induce resistance and their effects on the host microbiome.

Indexed as

Anti-Infective AgentsMetal NanoparticlesAnti-Bacterial AgentsBacteriaAnti-Bacterial AgentsAnti-Infective Agentsantibiotic resistancebiocompatibilitymetallic nanoparticlesmodulation of antimicrobial activitysynergy

Identifiers

PMID36768426
PMCPMC9917064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.